5月4日 - ** Rallybio RLYB.O 股价盘前飙升34.9%，至12.69美元
** UCB UCB.BR 周日表示，将以最高22亿美元的价格收购私营公司Candid Therapeutics (link)，以加强其免疫学产品线
** 今年3月 (link)，Rallybio曾宣布将与Candid合并，合并后的新公司将保留Candid名称，股票代码为CDRX
** 根据该协议，Rallybio股东将持有合并后公司约3.65%的股份，而Candid股东将持有约96.35%的股份
** 在Rallybio与Candid的交易于2026年年中完成前，UCB突然出手收购了Candid
** “我们认为拟议中的收购Candid交易与UCB的免疫学业务版图高度契合”——摩根大通分析师
** 截至上一交易日收盘，RLYB今年以来累计上涨71%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.